Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc.

KPTIยทNASDAQ

$9.23

+2.3%
HealthcareBiotechnology

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

At a Glance

Live Snapshot
Market Cap$209.18M
EPS-17.9300
P/E Ratio-0.41
Earnings Date07/30/2026

No Dividend Yield Data

KPTI has not reported any dividend yield values in the available annual periods.

No Dividend Payout Ratio Data

KPTI has not reported any dividend payout ratio values in the available annual periods.

No Net Dividends Paid Data

KPTI has not reported any net dividends paid values in the available annual periods.

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. Dividend History

KPTI ยท NASDAQ
10Y CAGR +0%
Latest $0
Annual $0
Stable dividend payments
Last Period: +0%

KPTI Dividend Payment History

KPTI ยท NASDAQ
DeclarationEx-DatePayment DateDividendAdjustedFrequencyGrowth
No dividend payment history available
kpti

Karyopharm Therapeutics Inc. Payout Ratio Analysis

KPTI ยท NASDAQ
Dividends Paid
0.00
2025
Net Income
-196.04M
2025
Payout Ratio
0.00%
2025

Dividend Sustainability Analysis

Payout Ratio
0.00%

Conservative payout with excellent safety margin. Company retains significant earnings for growth, acquisitions, or building cash reserves. Dividend is highly sustainable.

FCF Payout Ratio
0.0%

Negative free cash flow while paying dividends is a major red flag. Company burning cash and cannot sustain dividend without external financing.

Sustainability
At Risk

Dividend appears unsustainable based on current metrics. High probability of reduction or elimination. Proceed with caution.